Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07342309 · ClinicalTrials.gov registry record
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
A clinical trial of Metastatic Breast Cancer, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- 7,933
- Enrollment target
- 1
- Study location
NCT07342309 is a study of Metastatic Breast Cancer that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 7,933 participants, above the 148-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (5260% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07342309, a study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- 7,933 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to address the following key objectives in patients with HER2-altered mBC: Primary objectives * Estimate the prevalence of human epidermal growth factor receptor 2 positive (HER2+), human epidermal growth factor receptor 2 (HER2) mutation, cooccurrence of HER2+ and HER2 mutation among adult patients with metastatic breast cancer (mBC) * Among mBC patients with HER2+ and HER2 mutation, describe the following: * Baseline demographic and clinical characteristics * Treatment patterns during follow-up including 1L through fifth-line (5L) settings * Real-world overall survival (rwOS) for 1L through 5L Secondary objectives \- Among mBC patients with HER2+ and HER2 mutation, examine the following (as permissible in the study data): * Real-world progression-free survival (rwPFS) * Real-world time to discontinuation (rwTTD) * Real-world time to next treatment (rwTTNT) * Real-world overall response rate (rwORR)
Conditions Studied
Study Locations (1)
Connecticut
- Ridgefield - Ridgefield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,933 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07342309
The ClinicalTrials.gov registry entry for NCT07342309 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 7,933 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 148-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (5260% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07342309 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07342309 about?
NCT07342309 is a clinical study titled "Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States". This study aims to address the following key objectives in patients with HER2-altered mBC: Primary objectives * Estimate the prevalence of human epidermal growth factor receptor 2 positive (HER2+), human epidermal growth factor receptor 2 (HER2) mutation, cooccurrence of HER2+ and HER2 mutation am...
What is the current status of trial NCT07342309?
This trial is currently active not recruiting. The enrollment target is 7,933 participants. The study started on 2025-09-30. Estimated completion is 2026-06-30.
What conditions does trial NCT07342309 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
Who is sponsoring clinical trial NCT07342309?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07342309 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.